COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026 -
-
-
COMMUNIQUÉ DE PRESSE
Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
Newron Pharmaceuticals to present new analyses and updates on evenamide as treatment for schizophrenia at the 38th ECNP Congress 2025
